

Provided by:



## Thoracic Oncology Tumor Board 2024-2025

**Thoracic Oncology Tumor Board 2024-2025 - 2/9/2024**

**February 9, 2024**

**8:00 AM - 9:00 AM**

**online**

### **Target Audience**

This program has been designed for Internal Medicine - Hematology, Interventional Radiology And Diagnostic Radiology, Internal Medicine - Medical Oncology, Pathology - Clinical, Internal Medicine - Pulmonary Disease, Radiation Oncology, Thoracic And Cardiac Surgery, Pathology - Anatomic, Pathology - Clinical Informatics, Pathology - Cytopathology, Pathology - Hematopathology, Pathology - Pathology-Chemical, Pathology - Pathology-Medical Microbiology, Pathology - Pathology-Molecular Genetic, Internal Medicine - Hospice And Palliative Medicine, Radiology , Surgery - Hospice And Palliative Medicine, Radiology - Hospice And Palliative Medicine

### **Series Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

- 1 Delineate institutional and national pathways/guidelines in the management of thoracic malignancy.
- 2 Discuss multidisciplinary care and discussion to improve outcomes and quality of life
- 3 Describe the critical role of radiology and pathology in the multidisciplinary management of thoracic cancer
- 4 Discuss clinical trials at the ACC and throughout the nation and to enhance enrollment in clinical trials.

### **Accreditation**

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Designation of Credit**

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is for **1.00** contact hours.

**Pharmacists:** This activity is not approved for pharmacy contact hours

For more information, please contact  
**Megan Roy, Damaris Rodriguez**  
**(267) 271-9735, No phone on file**

**megan.roy@penntmedicine.upenn.edu, Damaris.Rodriguez@Penntmedicine.upenn.edu**

**Check your transcript online at <https://upenn.cloud-cme.com>**

**PAs:** Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

**Approved for (PSRM) patient safety/risk management designation**

**Acknowledgement of Commercial Support\***

None

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose, we consider relationships of the person involved to include financial relationships of a spouse or partner.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. Any peer reviewer with a potential conflict of interest will recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Elizabeth Gilbert, PA-C	Physician Assistant Planner	Nothing to disclose - 08/31/2023
Charuhas Deshpande, MD	Other Planning Committee Member	Nothing to disclose - 09/29/2023
Charu Aggarwal, MD, MPH	Other Planning Committee Member	Advisor-Astra Zeneca Pharmaceuticals   Advisor-Genentech (Relationship has ended)   Advisor-Merck & Co   Advisor-Janssen Pharmaceuticals (J&J)   Advisor-Sanofi Genzyme   Advisor-Pfizer, Inc. - 07/11/2023
John Kosteva, MD	Other Planning Committee Member	Nothing to disclose - 07/11/2023
Ana Kolansky, MD	Other Planning Committee Member	Nothing to disclose - 01/31/2024
Doraid Jarrar, MD	Other Planning Committee Member	Nothing to disclose - 08/28/2023
Melina Marmarelis, MD	Other Planning Committee Member	Consulting Fee-Novocure (Relationship has ended)   Honoraria-Bayer (Relationship has ended)   Consulting Fee-Astra Zeneca Pharmaceuticals   Consulting Fee-Janssen Pharmaceuticals (J&J)   Consulting Fee-Takeda Pharmaceuticals (Relationship has ended)   Consulting Fee-Bristol-Myers Squibb (Relationship has ended)   Grant or research

		<p>support-Eli Lilly   Consulting Fee-Blueprint Pharmaceuticals (Relationship has ended)   Advisor-Ikena   Grant or research support-Merck &amp; Co   Grant or research support-Astra Zeneca Pharmaceuticals   Stocks or stock options, excluding diversified mutual funds-Gilead Sciences, Inc (Relationship has ended)   Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Merck &amp; Co   Stocks or stock options, excluding diversified mutual funds-Portola Pharmaceuticals (Relationship has ended)   Stocks or stock options, excluding diversified mutual funds-Bluebird Biosciences (Relationship has ended)   Stocks or stock options, excluding diversified mutual funds-Novartis (Advanced Health Media) (Relationship has ended)   Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Johnson &amp; Johnson   Stocks or stock options, excluding diversified mutual funds-Pfizer, Inc. (Relationship has ended) - 07/11/2023</p>
william P levin, MD	Other Planning Committee Member	Nothing to disclose - 07/22/2023
Michael Costello, MD	Other Planning Committee Member	Nothing to disclose - 08/28/2023
steven Feigenberg, Md	Other Planning Committee Member	Honoraria-Astra Zeneca Pharmaceuticals (Relationship has ended)   Honoraria-Varian Medical Systems (Relationship has ended) - 08/28/2023
David DiBardino, MD	Other Planning Committee Member	Consulting Fee-Olympus   Consulting Fee-Johnson & Johnson   Consulting Fee-Intuitive Surgical (Relationship has ended) - 08/28/2023
Kevin Cong Ma, MD	Other Planning Committee Member	Grant or research support-Right Air   Grant or research support-Lung Therapeutics (Relationship has ended)   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Verona Pharmaceutical (Relationship has ended)   Consulting Fee-Pulmonx   Grant or research support-Pulmonx - 06/07/2023
Andrew Haas	Other Planning Committee Member	Consulting Fee-Olympus   Paid consultant-Serpex Medical   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novocure   Honoraria-Imedex   Consulting Fee-Mana Therapeutics (Relationship has ended)   Advisor-VisionAir -

		08/30/2023
John Kucharczuk, MD	Other Planning Committee Member	Speakers Bureau-Astra Zeneca Pharmaceuticals (Relationship has ended) - 01/03/2024
Taine Pechet, MD	Other Planning Committee Member	Nothing to disclose - 08/28/2023
Keith Cengel, MD, PhD	Co-Director, Faculty	Nothing to disclose - 08/28/2023
Roger B Cohen, MD	Other Planning Committee Member	Consulting Fee-Astra Zeneca Pharmaceuticals   Consulting Fee-Heat (Relationship has ended)   Grant or research support-Astra Zeneca Pharmaceuticals (Relationship has ended)   Grant or research support-Innate (Relationship has ended)   Consulting Fee-Actuate   Grant or research support-Macrogenics (Relationship has ended)   Grant or research support-Fstar   Grant or research support-Xencor (Relationship has ended)   Consulting Fee-Cantargia   Grant or research support-Cantargia - 07/11/2023
Lova Sun, MD	Other Planning Committee Member	Honoraria-Regeneron Pharmaceuticals, Inc. (Relationship has ended)   Grant or research support-Seattle Genetics   Grant or research support-Blueprint   Grant or research support-IO Biotech   Grant or research support-Erasca   Grant or research support-AbbVie, Inc.   Honoraria-Bayer (Relationship has ended) - 08/28/2023
Leslie Litzky, MD	Other Planning Committee Member	Nothing to disclose - 09/22/2023
Christine A Ciunci, MD	Other Planning Committee Member	Nothing to disclose - 11/30/2023
Megan Roy, RN	Nurse Planner	Speakers Bureau-Astra Zeneca Pharmaceuticals - 08/18/2023
Aditi Singh, MD	Other Planning Committee Member	Grant or research support-Jazz Pharmaceuticals - Institutional funding - 04/14/2023
Corey J Langer, FACP	Co-Director	Advisor-Merck & Co   Advisor-Astra Zeneca Pharmaceuticals   Consulting Fee-Gilead Sciences, Inc (Relationship has ended)   Advisor-Genentech   Advisor-Amgen   Advisor-Mirati   Grant or research support-Guardant   Grant or research support-Navire   Grant or research support-Fujifilm   Advisor-Novacure   Membership on Advisory Committees or Review Panels, Board Membership, etc.-RTOG Foundation   Advisor-Johnson & Johnson   Advisor-Pfizer, Inc.   Advisor-Eli Lilly -

		04/24/2023
--	--	------------

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected